Conference coverage
TCT 2013: Higher pacemaker rate marks difference between Medtronic’s, Edwards Lifesciences’ TAVI devices
TCT 2013: Renal denervation does everything
Renal denervation may have lost some of its hype over the course of the last year, but researchers are still findings new ways to utilize the technology to target new diseases.
TCT 2013: Is TAVI cost-effective in operable patients?
TCT 2013: Medtronic unveils full 1-year results from ADVANCE CoreValve trial
TCT 2013: Device makers challenge Big Pharma for stroke prevention in afib patients
TCT 2013: Docs trade barbs over LAA closure
Children’s hospital CEOs: Pediatric healthcare is at a ‘tipping point’
To summarize the state of pediatric health care today, Steven Altschuler, MD, president and CEO of Children’s Hospital of Philadelphia (CHOP), quoted the 1963 movie The Leopard: "Everything must change, so that everything can stay the same."
ESC 2013: Pacemakers set life expectancy back to normal, researchers say
A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam.
A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.
ESC 2013: Medtronic’s Symplicity hypertension treatment still promising at 1 and 3 years
New data on Medtronic’s (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.
A proverbial ‘Disneyland Sweepstakes’ in med device sends 1 company to AdvaMed 2013
It’s the proverbial "Disneyland Sweepstakes" in the medical device world: an all-expenses-paid trip to AdvaMed’s 2013 conference will go to 1 start-up company through a scholarship contest sponsored by RCT BioVentures.
The winner will have to prove true start-up chops – a company with a great technology but not a lot of walking-around money. Ideally, RCT BioVentures is looking to fund a company still in the pre-Series-A phase.